Global Genitourinary Drugs Market Research Report to 2027 - Increasing Prevalence of Genitourinary Disorders is Driving Growth

DUBLIN, April 26, 2022 /PRNewswire/ -- The "Genitourinary Drugs Market Research Report by Indication (Benign Prostatic Hyperplasia, Bladder Cancer, and Cervical Cancer), Product, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

The Global Genitourinary Drugs Market size was estimated at USD 32.60 billion in 2021, USD 33.24 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 2.11% to reach USD 36.97 billion by 2027.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Genitourinary Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Genitourinary Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Genitourinary Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Genitourinary Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Genitourinary Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Genitourinary Drugs Market?
6. What is the market share of the leading vendors in the Global Genitourinary Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Genitourinary Drugs Market?

Key Topics Covered:

1. Preface

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of genitourinary disorders
5.1.1.2. Rising number of pipeline drugs
5.1.1.3. Growing concerns about urinary incontinence and impotence
5.1.2. Restraints
5.1.2.1. Availability of counterfeit and generics drugs in the market
5.1.3. Opportunities
5.1.3.1. Collaborative R&D efforts by the pharma companies
5.1.3.2. Growing investment in healthcare for improved treatments
5.1.4. Challenges
5.1.4.1. Lack of compliance to medication
5.1.4.2. Continual patent expirations
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict

6. Genitourinary Drugs Market, by Indication
6.1. Introduction
6.2. Benign Prostatic Hyperplasia
6.3. Bladder Cancer
6.4. Cervical Cancer
6.5. Erectile Dysfunction
6.6. Hematuria
6.7. Interstitial Cystitis
6.8. Ovarian Cancer
6.9. Prostate Cancer
6.10. Renal Cancer
6.11. Sexually Transmitted Diseases
6.12. Urinary Incontinence & Overactive Bladder
6.13. Urinary Tract Infections

7. Genitourinary Drugs Market, by Product
7.1. Introduction
7.2. Anti-infectives
7.3. Gynecological
7.4. Hormonal Therapy
7.5. Urologicals

8. Americas Genitourinary Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Genitourinary Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand

10. Europe, Middle East & Africa Genitourinary Drugs Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Abbott
12.2. Allergan
12.3. Antares Pharma
12.4. Asieris Pharmaceuticals
12.5. Astellas Pharma Inc
12.6. AstraZeneca
12.7. Bayer AG
12.8. Bristol-Myers Squibb Co.
12.9. Cipla USA Inc.
12.10. Eli Lilly and Company
12.11. F. Hoffmann-La Roche Ltd
12.12. Genentech, Inc.
12.13. GlaxoSmithKline
12.14. Ionis Pharmaceuticals, Inc.
12.15. Johnson & Johnson Services, Inc.
12.16. Melinta Therapeutics Inc.
12.17. Merck & Co., Inc.
12.18. Novartis AG
12.19. Pfizer, Inc.
12.20. Teva Pharmaceutical Industries Ltd.

13. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/4sml0

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets